
    
      Three parallel cohort, multicenter, open-label, phase I/II clinical trial to analyze the
      safety and feasibility of PD-1 inhibition with Nivolumab given concomitantly with standard
      radiotherapy regimens in the treatment of esophageal cancer.

      Cohort A: Advanced/inoperable esophageal cancer, eligible for palliative radiotherapy of the
      primary tumor.

      Cohort B: Inoperable esophageal cancer without metastases, eligible for definitive
      chemoradiotherapy Cohort C: Operable esophageal cancer eligible for neoadjuvant
      chemoradiotherapy
    
  